Development and testing of nootkatone-containing skin repellents
Ended Definitive Contract Awarded Last action
- Contract number
- 75D30122C15711
- Awardee
-
Evolva AG UEI USMKPLLM7GJ3
- Awarding agency
-
CDC Pittsburgh
Centers for Disease Control and Prevention, Department of Health and Human Services
- Obligated
- $0
Award facts
- Opportunity
-
- 75D30122R72513 Solicitation number
- Contract value 0% obligated
- $540,891.50 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- PSC
- AJ11 General Science And Technology R&D Services; General Science And Technology; Basic Research
- Set-aside
- No set-aside
- Competition
- 6 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- 4153 Reinach, Switzerland
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $540,892 |
About this award
The Centers for Disease Control and Prevention (CDC) Pittsburgh awarded a definitive firm fixed-price contract to Evolva AG (doing business as Evolva LTD) on September 30, 2022, with a ceiling value of $540,891.50. The contract, which was not set aside for any socioeconomic category, funded the development and testing of nootkatone-containing skin repellents. Nootkatone is a naturally occurring compound derived from grapefruit that has demonstrated effectiveness as an insect repellent. The work was performed at Evolva's facility in Reinach, Switzerland, with a completion deadline of September 30, 2024. This contract aligns with the CDC's mission to develop and evaluate novel vector control and personal protection strategies against disease-carrying insects.
Evolva AG, a Swiss biotechnology company specializing in fermentation and synthetic biology, was well-positioned to execute this development and testing initiative given its expertise in producing specialty chemicals and natural compounds. The CDC's interest in nootkatone-based repellents reflects the agency's broader efforts to identify effective alternatives to traditional synthetic repellents like DEET for use in public health programs and personal protection against tick-borne illnesses and other vector-borne diseases. The firm fixed-price structure established clear cost accountability for this applied research and product development effort.
Quick answers
Who was awarded contract 75D30122C15711?
75D30122C15711 was awarded to Evolva AG by CDC Pittsburgh (Centers for Disease Control and Prevention) on September 30, 2022.
How much is contract 75D30122C15711 worth?
The government has obligated $0 on 75D30122C15711. Its current value, with exercised options, is $540,892.
Was contract 75D30122C15711 competed?
The government received 6 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award